Long-term administration of angiotensin (1-7) prevents heart and lung dysfunction in a mouse model of type 2 diabetes (db/db) by reducing oxidative stress, inflammation and pathological remodeling

Pharmacological Research

Volumn 107, Issue , 2016, Pages 372-380

  Papinska, Anna M ^a   Soto, Maira ^a   Meeks, Christopher J ^a   Rodgers, Kathleen E ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Angiotensin (1 7); Diabetes mellitus; Heart failure; Lung congestion; Remodeling

Indexed keywords

ANGIOTENSIN[1-7]; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA; ANGIOTENSIN I; ANGIOTENSIN I (1-7); ANTIDIABETIC AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CARDIOTONIC AGENT; CYTOKINE; PEPTIDE FRAGMENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BODY MASS; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; HEART OUTPUT; HEART STROKE VOLUME; HEART VENTRICLE HYPERTROPHY; HYPERGLYCEMIA; LIPID STORAGE; LUNG CONGESTION; LUNG FIBROSIS; MACROPHAGE MIGRATION; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; ANIMAL; BLOOD; CARDIAC MUSCLE; DIABETES MELLITUS, TYPE 2; DISEASE MODEL; DRUG EFFECTS; FIBROSIS; HEART; LIPID METABOLISM; LUNG; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANGIOTENSIN I; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; APOPTOSIS; CARDIOTONIC AGENTS; CYTOKINES; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; FIBROSIS; HEART; HYPOGLYCEMIC AGENTS; LIPID METABOLISM; LUNG; MALE; MICE; MYOCARDIUM; OXIDATIVE STRESS; PEPTIDE FRAGMENTS;

EID: 84963529414     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.02.026     Document Type: Article

References (41)

1. J.C. Romero, and J.F. Reckelhoff Role of angiotensin and oxidative stress in essential hypertension Hypertension 34 October (4) 1999 943 949
2. M.C. Zimmerman, E. Lazartigues, R.V. Sharma, and R.L. Davisson Hypertension caused by angiotensin II infusion involves increased superoxide production in the central nervous system Circ. Res. 95 July (2) 2004 210 216
3. D.N. Muller, R. Dechend, E.M.A. Mervaala, J.K. Park, F. Schmidt, A. Fiebeler, and et al. NF- κB inhibition ameliorates angiotensin II-Induced inflammatory damage in rats Hypertension 35 January (1) 2000 193 201
4. Y. Suzuki, M. Ruiz-Ortega, O. Lorenzo, M. Ruperez, V. Esteban, and J. Egido Inflammation and angiotensin II Int. J. Biochem. Cell Ciol. 35 March (27) 2003 881 900
5. T. Chabrashvili, C. Kitiyakara, J. Blau, A. Karber, S. Aslam, W.J. Welch, and et al. Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression AJP - regulatory Integr. Comp. Physiol. 285 July (1) 2003 R117 R124
6. J. Sadoshima, and S. Izumo Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts critical role of the AT1 receptor subtype Circ. Res. 73 September (3) 1993 413 423
7. E.J. Henriksen Improvement of insulin sensitivity by antagonism of the renin-angiotensin system. AJP - regulatory Integr. Comp. Physiol. 293 June (3) 2007 R974 R980
8. J.A. Olivares-Reyes, A. Arellano-Plancarte, and J.R. Castillo-Hernandez Angiotensin II and the development of insulin resistance: implications for diabetes Mol. Cell. Endocrinol. 302 April (2) 2009 128 139
9. M. Bader, R.A. Santos, T. Unger, and U.M. Steckelings New therapeutic pathways in the RAS J. Renin Angiotensin Aldosterone Syst. 13 December (4) 2012 505 508
10. P.-P. Hao, Y.-G. Chen, Y.-P. Liu, M.-X. Zhang, J.-M. Yang, F. Gao, and et al. Association of plasma angiotensin-(1-7) level and left ventricular function in patients with type 2 diabetes mellitus PLoS One 8 May (5) 2013 e62788
11. N.I.H., National Diabetes Education Program, retrieved from: http://ndep.nih.gov/media/CVD-FactSheet.pdf, (accessed on 10.01.15).
12. S. Kim, and H. Iwao Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases Pharmacol. Rev. 52 March (1) 2000 11 34
13. C. Yoshimura, T. Oga, K. Chin, M. Takegami, K.-I. Takahashi, K. Sumi, and et al. Relationships of decreased lung function with metabolic syndrome and obstructive sleep apnea in Japanese males Intern. Med. 51 17 2012 2291 2297
14. L.M. Pinto Pereira, T.A.R. Seemungal, S. Teelucksingh, and B.S. Nayak Restrictive pulmonary deficit is associated with inflammation in sub-optimally controlled obese diabetics J. Thorac. Dis. 5 June (3) 2013 289 297
15. S.F. Ehrlich, C.P.J. Quesenberry, S.K. Van Den Eeden, J. Shan, and A. Ferrara Patients diagnosed with diabetes are at increased risk for asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, and pneumonia but not lung cancer Diabetes Care 33 January (1) 2010 55 60
16. W. Dalleywater, H.A. Powell, R.B. Hubbard, and V. Navaratnam Risk factors for cardiovascular disease in people with idiopathic pulmonary fibrosis: a population-based study Chest 147 January (1) 2015 150 156
17. N.M. Mordwinkin, C.J. Meeks, S.S. Jadhav, T. Espinoza, N. Roda, G.S. diZerega, and et al. Angiotensin-(1-7) administration reduces oxidative stress in diabetic bone marrow Endocrinology 153 April (5) 2012 2189 2197
18. A.M. Papinska, N.M. Mordwinkin, C.J. Meeks, S.S. Jadhav, and K.E. Rodgers Angiotensin-(1-7) administration benefits cardiac, renal, and progenitor cell function in db/db mice Br. J. Pharmacol. July (29) 2015 1 11
19. R.M. Lang, M. Bierig, R.B. Devereux, F.A. Flachskampf, E. Foster, P.A. Pellikka, and et al. Recommendations for chamber quantification Eur. J. Echocardiogr. 7 March (2) 2006 79 108
20. C.B. Walton, C.D. Anderson, R. Boulay, and R.V. Shohet Introduction to the ultrasound targeted microbubble destruction technique JoVE 52 2011
21. T. Enomoto, J. Usuki, A. Azuma, T. Nakagawa, and S. Kudoh Diabetes mellitus may increase risk for idiopathic pulmonary fibrosis Chest 123 June (6) 2003 2007 2011
22. S.F. Ehrlich, C.P.J. Quesenberry, S.K. Van Den Eeden, J. Shan, and A. Ferrara Patients diagnosed with diabetes are at increased risk for asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, and pneumonia but not lung cancer Diabetes Care 33 January (1) 2010 55 60
23. C. Christoffersen, E. Bollano, M.L.S. Lindegaard, E.D. Bartels, J.P. Goetze, C.B. Andersen, and et al. Cardiac lipid accumulation associated with diastolic dysfunction in obese mice Endocrinology 144 August (8) 2003 3483 3490
24. A. Daniels, M. van Bilsen, B.J.A. Janssen, A.E. Brouns, J.P.M. Cleutjens, T.H.M. Roemen, and et al. Impaired cardiac functional reserve in type 2 diabetic db/db mice is associated with metabolic, but not structural, remodelling Acta Physiol. 200 September (1) 2010 11 22
25. Y.T. Zhou, P. Grayburn, A. Karim, M. Shimabukuro, M. Higa, D. Baetens, and et al. Lipotoxic heart disease in obese rats: implications for human obesity PNAS 97 February (4) 2000 1784 1789
26. M.A. Konstam, J.D. Neaton, K. Dickstein, H. Drexler, M. Komajda, F.A. Martinez, and et al. Effects of high-dose versus low-dose losartan on clinicaloutcomes in patients with heart failure (HEAAL study):a randomised, double-blind trial Lancet 374 November (28) 2009 1840 1848 (9704)
27. J. Yang, Y. Tan, F. Zhao, Z. Ma, Y. Wang, S. Zheng, and et al. Angiotensin II plays a critical role in diabetic pulmonary fibrosis most likely via activation of NADPH oxidase-mediated nitrosative damage AJP - Endocrinol. Metab. 301 July (1) 2011 E132 44
28. I.F. Benter, M.H.M. Yousif, C. Cojocel, M. Al-Maghrebi, and D.I. Diz Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction AJP - Heart Circulat. Physiol. 292 January (1) 2007 H666 72
29. Y. Marcus, G. Shefer, K. Sasson, F. Kohen, R. Limor, O. Pappo, and et al. Angiotensin 1-7 as means to prevent the metabolic syndrome Diabetes 5 December (17) 2012 1 10
30. M.H.M. Yousif, G.S. Dhaunsi, B.M. Makki, B.A. Qabazard, S. Akhtar, and I.F. Benter Characterization of Angiotensin-(1-7) effects on the cardiovascular system in an experimental model of type-1 diabetes Pharmacol. Res. 66 September (3) 2012 269 275
31. J. Mori, V.B. Patel, O. Abo Alrob, R. Basu, T. Altamimi, J. DesAulniers, and et al. Angiotensin 1-7 ameliorates diabetic cardiomyopathy and diastolic dysfunction in db/db mice by reducing lipotoxicity and inflammation Circulation: Heart Fail. 7 March (2) 2014 327 339
32. K.E. Rodgers, J. Oliver, and G.S. diZerega Phase I/II Dose escalation study of angiotensin 1-7 [A(1-7)] administered before and after chemotherapy in patients with newly diagnosed breast cancer Cancer Chemother. Pharmacol. 57 May (5) 2006 559 568
33. D.B. Averill, Y. Ishiyama, M.C. Chappell, and C.M. Ferrario Cardiac angiotensin-(1-7) in ischemic cardiomyopathy Circulation 108 October (17) 2003 2141 2146
34. R.A. Santos, J.M. Brum, K.B. Brosnihan, and C.M. Ferrario The renin-angiotensin system during acute myocardial ischemia in dogs Hypertension 15 February (1) 1990 121 122 2-Suppl.
35. L.S. Zisman, G.E. Meixell, M.R. Bristow, and C.C. Canver Angiotensin-(1-7) formation in the intact human heart: in vivo dependence on angiotensin II as substrate Circulation 108 October (14) 2003 1679 1681
36. K. Eguchi, B. Boden-Albala, Z. Jin, T. Rundek, R.L. Sacco, S. Homma, and et al. Association between diabetes mellitus and left ventricular hypertrophy in a multi-Ethnic population Am. J. Cardiol. 101 July (25) 2008 1787 1791
37. A.R. Wende, and E.D. Abel Lipotoxicity in the heart Biochim. Biophys. Acta 1801 March (3) 2010 311 319
38. V. Palmieri, R.P. Tracy, M.J. Roman, J.E. Liu, L.G. Best, J.N. Bella, and et al. Relation of left ventricular hypertrophy to inflammation and albuminuria in adults with type 2 diabetes: the strong heart study Diabetes Care 26 October (10) 2003 2764 2769
39. G.J. Rey-Parra, A. Vadivel, L. Coltan, A. Hall, F. Eaton, M. Schuster, and et al. Angiotensin converting enzyme 2 abrogates bleomycin-induced lung injury J. Mol. Med. 90 June (6) 2012 637 647
40. Y. Meng, T. Li, G.-S. Zhou, Y. Chen, C.-H. Yu, M.-X. Pang, and et al. The angiotensin-converting enzyme 2/angiotensin (1-7)/Mas axis protects against lung fibroblast migration and lung fibrosis by inhibiting the NOX4-derived ROS-mediated RhoA/Rho kinase pathway Antioxid. Redox Signaling January (3) 2015 241 258
41. S.K. Agarwal, G. Heiss, R.G. Barr, P.P. Chang, L.R. Loehr, L.E. Chambless, and et al. Airflow obstruction, lung function, and risk of incident heart failure: the atherosclerosis risk in communities (ARIC) study Eur. J. Heart Fail. 14 April (4) 2012 414 422